AIM ImmunoTech (NYSE:AIM) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS

AIM ImmunoTech (NYSE:AIMGet Rating) released its earnings results on Monday. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01), Fidelity Earnings reports. AIM ImmunoTech had a negative return on equity of 30.30% and a negative net margin of 14,273.88%.

Shares of AIM traded down $0.04 during trading on Wednesday, reaching $0.95. 235,770 shares of the company traded hands, compared to its average volume of 233,819. The stock has a 50-day simple moving average of $1.02 and a 200-day simple moving average of $1.06. AIM ImmunoTech has a twelve month low of $0.55 and a twelve month high of $2.40. The stock has a market cap of $44.18 million, a PE ratio of -2.38 and a beta of -0.60.

Institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its position in shares of AIM ImmunoTech by 6.0% during the 3rd quarter. Geode Capital Management LLC now owns 372,953 shares of the company’s stock worth $753,000 after acquiring an additional 21,203 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of AIM ImmunoTech by 166.3% during the third quarter. Dimensional Fund Advisors LP now owns 370,643 shares of the company’s stock worth $749,000 after buying an additional 231,483 shares during the last quarter. Millennium Management LLC purchased a new position in AIM ImmunoTech in the 3rd quarter valued at $110,000. Renaissance Technologies LLC acquired a new position in shares of AIM ImmunoTech during the fourth quarter worth about $649,000. Finally, Citadel Advisors LLC acquired a new position in AIM ImmunoTech during the 4th quarter worth approximately $37,000. Institutional investors own 16.05% of the company’s stock.

AIM ImmunoTech Company Profile (Get Rating)

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).

Recommended Stories

Earnings History for AIM ImmunoTech (NYSE:AIM)

Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with's FREE daily email newsletter.